Fishel Melissa L, Kelley Mark R
Department of Pediatrics (Section of Hematology/Oncology), Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, United States.
Mol Aspects Med. 2007 Jun-Aug;28(3-4):375-95. doi: 10.1016/j.mam.2007.04.005. Epub 2007 May 3.
With our growing understanding of the pathways involved in cell proliferation and signaling, targeted therapies, in the treatment of cancer are entering the clinical arena. New and emerging targets are proteins involved in DNA repair pathways. Inhibition of various proteins in the DNA repair pathways sensitizes cancer cells to DNA damaging agents such as chemotherapy and/or radiation. We study the apurinic endonuclease 1/redox factor-1 (Ape1/Ref-1) and believe that its crucial function in DNA repair and reduction-oxidation or redox signaling make it an excellent target for sensitizing tumor cells to chemotherapy. Ape1/Ref-1 is an essential enzyme in the base excision repair (BER) pathway which is responsible for the repair of DNA caused by oxidative and alkylation damage. As importantly, Ape1/Ref-1 also functions as a redox factor maintaining transcription factors in an active reduced state. Ape1/Ref-1 stimulates the DNA binding activity of numerous transcription factors that are involved in cancer promotion and progression such as AP-1 (Fos/Jun), NFkappaB, HIF-1alpha, CREB, p53 and others. We will discuss what is known regarding the pharmacological targeting of the DNA repair activity, as well as the redox activity of Ape1/Ref-1, and explore the budding clinical utility of inhibition of either of these functions in cancer treatment. A brief discussion of the effect of polymorphisms in its DNA sequence is included because of Ape1/Ref-1's importance to maintenance and integrity of the genome. Experimental modification of Ape1/Ref-1 activity changes the response of cells and of organisms to DNA damaging agents, suggesting that Ape1/Ref-1 may also be a productive target of chemoprevention. In this review, we will provide an overview of Ape1/Ref-1's activities and explore the potential of this protein as a target in cancer treatment as well as its role in chemoprevention.
随着我们对细胞增殖和信号传导相关途径的理解不断加深,癌症治疗中的靶向疗法正在进入临床领域。新出现的靶点是参与DNA修复途径的蛋白质。抑制DNA修复途径中的各种蛋白质可使癌细胞对化疗和/或放疗等DNA损伤剂敏感。我们研究了脱嘌呤嘧啶内切酶1/氧化还原因子-1(Ape1/Ref-1),并认为其在DNA修复以及氧化还原信号传导中的关键功能使其成为使肿瘤细胞对化疗敏感的理想靶点。Ape1/Ref-1是碱基切除修复(BER)途径中的一种必需酶,该途径负责修复由氧化和烷基化损伤引起的DNA。同样重要的是,Ape1/Ref-1还作为一种氧化还原因子,将转录因子维持在活性还原状态。Ape1/Ref-1刺激许多参与癌症促进和进展的转录因子的DNA结合活性,如AP-1(Fos/Jun)、NFκB、HIF-1α、CREB、p53等。我们将讨论关于Ape1/Ref-1的DNA修复活性以及氧化还原活性的药物靶向作用的已知信息,并探索抑制这些功能中的任何一种在癌症治疗中的新兴临床应用。由于Ape1/Ref-1对基因组的维持和完整性很重要,因此还简要讨论了其DNA序列多态性的影响。对Ape1/Ref-1活性的实验性修饰会改变细胞和生物体对DNA损伤剂的反应,这表明Ape1/Ref-1也可能是化学预防的有效靶点。在这篇综述中,我们将概述Ape1/Ref-1的活性,并探讨该蛋白作为癌症治疗靶点的潜力及其在化学预防中的作用。